Products for Research Use Only

NF110

CAT: 0804-HY-108671-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-108671-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
NF110 is a P2X3 receptor antagonist (Ki = 36 nM) and inactive toward P2Y receptors stably expressed (IC50s > 10 M) . NF110 blocks alphabeta-methylene-ATP-induced currents (IC50 = 527 nM) in rat dorsal root ganglia neurons[1].
CAS Number
111150-22-2
UNSPSC
12352005
Target
P2X Receptor
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/nf110.html
Purity
93.6
Solubility
H2O : 40 mg/mL (ultrasonic; warming)
Smiles
O=C(NC1=CC(C(NC2=CC=C(S(=O)(O[Na])=O)C=C2)=O)=CC(C(NC3=CC=C(S(=O)(O[Na])=O)C=C3)=O)=C1)NC4=CC(C(NC5=CC=C(S(=O)(O[Na])=O)C=C5)=O)=CC(C(NC6=CC=C(S(=O)(O[Na])=O)C=C6)=O)=C4
Molecular Formula
C41H28N6Na4O17S4
Molecular Weight
1096.91
References & Citations
[1]Hausmann R, et al. The suramin analog 4,4',4'',4'''- (carbonylbis (imino-5,1,3-benzenetriylbis (carbonylimino) ) ) tetra-kis-benzenesulfonic acid (NF110) potently blocks P2X3 receptors: subtype selectivity is determined by location of sulfonic acid groups. Mol Pharmacol. 2006;69 (6) :2058-2067.|[2]Dhar S, et al. Antitumour activity of suramin analogues in human tumour cell lines and primary cultures of tumour cells from patients. Eur J Cancer. 2000;36 (6) :803-809.|[3]Su L, et al. Identification of HMGA2 inhibitors by AlphaScreen-based ultra-high-throughput screening assays. Sci Rep. 2020;10 (1) :18850. Published 2020 Nov 2.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
P2X3 Receptor